This article is more than 5 years old. Information may no longer be current.

Akorn receives IND clearance to develop ocular anesthesia drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BUFFALO GROVE, Ill. — Akorn Inc. has received investigational new drug clearance to initiate a pivotal clinical trial of a new drug for ocular anesthesia, the company announced.

The trial will evaluate Akorn's AK-1015 in a four-arm study involving 200 patients, which is expected to begin this month. The company has signed an agreement with a contract research organization firm to deploy and monitor the trial. The company said intends to file a new drug application in 2007, with a potential product launch in 2008, according to a press release.